An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects

Trial Profile

An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Acute myeloid leukaemia; Astrocytoma; Biliary cancer; Colorectal cancer; Glioma; Liver cancer; Malignant melanoma; Multiple myeloma; Neurofibromatoses; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Thyroid cancer; Uveal melanoma
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Mar 2017 Results of pooled analysis of ten phase I studies including this study published in the European Journal of Clinical Pharmacology
    • 26 Dec 2016 Results of two phase I studies including this study published in the Journal of Clinical Pharmacology
    • 11 Oct 2016 Results of pooled analysis of PK data from this and other 9 trials ( NCT01635023, NCT01974349, NCT02056392, NCT02322749, NCT02238782, NCT02063230, NCT02093728, NCT02046850, NCT01960374) presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top